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To the editor: Anticoagulant treatment of venous thromboembolism (VTE) in cancer patients 
requires careful attention as rates of recurrent VTE and bleeding complications during treatment are 
substantially higher than in non-cancer patients. Current clinical practice guidelines recommend 
treatment with low molecular weight heparin (LMWH) over warfarin or non-vitamin K antagonist 
oral anticoagulants (NOAC). However, there is a growing interest in the use of NOACs for cancer 
patients though their safety and efficacy remain unclear. The first two head-to-head comparisons 
between LMWH and NOAC in cancer patients were published in 2017, other trials are ongoing [1, 
2].  
 
While we await results of the ongoing trials to clarify the value of NOACs in cancer patients, we 
commend the effort by Streiff et al [3] who recently published real world data in the American 
Journal of Hematology on the safety and effectiveness of anticoagulant treatment regimens for 
cancer-associated VTE. Using claims data from the US Humana database, the authors assessed the 
comparative effectiveness and safety of LMWH, warfarin, and rivaroxaban in a cohort of newly 
diagnosed cancer patients treated for VTE during 2013-2015. Using three sets of pairwise inverse 
probability of treatment (IPT) weighted comparisons of „rivaroxaban users vs. LMWH users‟, 
„rivaroxaban vs. warfarin‟, and „warfarin vs. LMWH‟, the authors concluded that treatment with 
rivaroxaban is associated with significantly lower rates of recurrent VTE and similar rates of major 
bleeding as treatment with LMWH or warfarin. 
 
However, based on the findings reported by Streiff et al., we find it difficult to answer the clinical 
question of interest “what should be the treatment of choice for cancer patients who could 
reasonably get any of the three treatments regimens?” To answer this, the cohorts should have 
represented exchangeable patients among whom the comparative effectiveness and safety of the 
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three treatment regimens could have been compared; essentially reflecting a head-to-head 
comparison resembling a three-arm RCT, where patients are in clinical equipoise at the time of 
randomization.  
 
Assumming no unmeasured confounding and no treatment-effect heterogeneity the pairwise 
comparisons would yield unbiased estimates of an average treatment effect. However, these 
assumptions are not often held when using observational data. In the presence of treatment-effect 
heterogeneity, use of IPT weighting is an appropriate analytic approach, since this allow for 
estimation of the average treatment effect in the population (i.e. warfarin users, rivaroxaban users, 
and LMWH users). This theoretically mimics a randomized trial with three treatment arms, 
assuming that the IPT weighting sufficiently accounted for observed confounding. However, the 
choice of pairwise weighted analyses correspond to conducting three RCTs with different sets of 
inclusion and exclusion criteria per pair of treatments. Instead of using an analytic strategy that 
accounted for the multilevel treatments, the authors chose to apply three separate pairwise 
comparisons, which runs the risk of comparing estimates that are based on vastly different cohorts. 
With that approach it is unknown (and unlikely) if e.g. the rivaroxaban population resemble the 
same patients in the rivaroxaban-LMWH comparison as in the rivaroxaban-warfarin comparison. 
As appears from Table 1 in the paper, the prevalence of rivaroxaban users with very high risk 
(13.5% vs. 8.7%) and high risk cancer (34.7% vs. 29.1%) differ substantially in the treatment 
comparisons groups. This complicates the comparison of the three treatment regimens and the 
interpretation is not as straightforward as it may seem when reading the paper.  
 
We further draw the attention to the magnitude of the event rates reported in Figure 1. These are 
unusual high compared with previous trials and real-world data [1, 2, 4], and we therefore raise a 
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concern on the generalizability of the study findings. We do not concur with the author‟s statement 
that failure to account for the competing risk of death was not a limitation as the assumption was 
that “the rates were the same across treatment cohorts”. In our opinion, the reliability of the reported 
hazard rates is more a question about the generalizability of the study cohort. If the mortality risk in 
this setting is lower than in other cancer cohorts, this would lead to exaggerated event rates and 
therefore also imprecisely estimated cause-specific hazard ratios.  
 
In addition, the authors used the Kaplan-Meier estimator to contrasts events between treatment 
allocations. However, in the prescence of competing risks, the Kaplan-Meier estimator overestimate 
the cumulative risk of recurrent VTE and major bleeding [5]. This is paticularly evident in 
populations with high mortality rates such as cancer patients. For the Kaplan-Meier estimator to be 
valid, censoring at the time of death should be noninformative. In other words, the risk of events in 
patients who are censored because of death should not differ from that of patients still at risk. 
Obviously, we know that dead persons are no longer at risk of recurrent VTE or major bleeding, 
and this violates the assumption about noninformative censoring. As a consequence, results of the 
log-rank tests is also invalid [6]. Thus, the failure to account for the competing risk of death, led to 
overestimation of the cumulative probability of both recurrence and bleeding outcomes.  
 
The anticipated trials on NOACs for cancer patients will likely represent a highly selected subset of 
cancer patients encountered in routine clinical care. In this respect, data on the uses of NOACs in 
clinical practice (i.e. real-world data) is important. Additional investigations are encouraged to fill 
the knowledge gap on safe prescribing of NOACs in this challenging patient segment. 
Notwithstanding, such investigations requires conscientiously study designs and cautious 
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interpretation that, however, would allow for causal inference between choice of treatment and 
treatment outcomes.  
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